Ginkgo Biloba for Tinnitus

Tinnitus — the perception of sound (ringing, hissing, buzzing, roaring) without a corresponding external acoustic source — affects an estimated 10-15% of adults worldwide, of whom roughly 1-2% experience it as severe and disabling. Conventional medicine has no consistently effective pharmacotherapy for tinnitus. Ginkgo biloba is, paradoxically, the single most-prescribed pharmacotherapy for tinnitus in Germany and across much of Europe — not because the evidence is overwhelming but because nothing else works any better and the safety profile of standardized EGb 761 is favorable. The evidence base is genuinely mixed: the von Boetticher 2011 systematic review of EGb 761 RCTs concluded modest but real benefit; the Cochrane 2013 review (Hilton et al.) concluded inconclusive evidence; the underlying mechanism via cochlear microcirculation improvement and neuroprotection of inner-ear hair cells is biologically plausible; and individual response varies dramatically from "no effect" to "dramatic resolution." The honest framing for patients: ginkgo at 240 mg/day for 12 weeks is a reasonable trial in subjective tinnitus of suspected vascular origin, with the understanding that perhaps one-third of patients will derive meaningful benefit, one-third will see no change, and one-third will see partial improvement.

Table of Contents

1. What Is Tinnitus?
2. von Boetticher 2011 — The Modern Positive Meta-Analysis
3. The Cochrane 2013 Review — Mixed Evidence
4. Cochlear Blood Flow — The Microcirculation Mechanism
5. Neuroprotection of Inner-Ear Hair Cells
6. Central Auditory Pathway Effects
7. Why German Practice Diverges from US Practice
8. Sudden Sensorineural Hearing Loss
9. Dosing Protocol — What Actually Works
10. Cautions — Tinnitus Population Specific
11. Key Research Papers
12. Connections

What Is Tinnitus?

Tinnitus is the perception of sound (typically described as ringing, buzzing, hissing, roaring, clicking, or musical tones) in the absence of an external acoustic source. It is a symptom, not a disease, and arises from dozens of different underlying conditions:

• Noise-induced hearing loss — the most common cause. Chronic exposure to loud noise damages outer hair cells in the cochlea, producing both high-frequency hearing loss and tinnitus typically pitched at the frequency of greatest hearing loss
• Presbycusis — age-related hearing loss. By age 65 approximately 30% of adults have measurable hearing loss; many have tinnitus
• Ototoxic medications — aminoglycoside antibiotics (gentamicin, tobramycin), platinum chemotherapy (cisplatin), loop diuretics (furosemide at high IV dose), high-dose aspirin and other salicylates, quinine
• Cerumen impaction — the cause that is most easily curable. Always check the ears.
• Meniere's disease — the triad of episodic vertigo, fluctuating sensorineural hearing loss, and unilateral low-pitched tinnitus, with aural fullness
• Acoustic neuroma (vestibular schwannoma) — unilateral tinnitus with asymmetric hearing loss warrants MRI of the internal auditory canal
• Vascular tinnitus — pulsatile tinnitus suggests vascular etiology (carotid stenosis, AVM, dural fistula, idiopathic intracranial hypertension); workup includes imaging
• TMJ dysfunction — mechanical/somatic tinnitus often modulated by jaw position
• Cervical spine dysfunction — cervicogenic tinnitus modulated by neck position
• Idiopathic / no identifiable cause — a substantial fraction of subjective tinnitus has no clear underlying mechanism on conventional workup

The clinical taxonomy that matters for ginkgo response is the subjective vs objective distinction and the vascular vs non-vascular distinction. Subjective tinnitus (perceived only by the patient, the vast majority of cases) is the population where ginkgo has been studied. Vascular tinnitus and tinnitus accompanying sudden sensorineural hearing loss or presbycusis with reduced cochlear perfusion are the populations most likely to respond. Objective tinnitus (audible to an examiner with a stethoscope over the ear, typically caused by glomus tympanicum, palatal myoclonus, or other mechanical sources) is not a ginkgo indication.

Conventional treatment options are limited: no FDA-approved drug exists specifically for tinnitus in the United States. Off-label use of antidepressants (nortriptyline, amitriptyline) has modest evidence for severe distressing tinnitus, primarily through reducing the distress rather than the perception. Tinnitus retraining therapy (TRT) and cognitive behavioral therapy have stronger evidence than any pharmacologic approach. Sound masking (white noise generators, hearing aids that amplify ambient sound) is the highest-evidence non-pharmacologic intervention. Within this generally bleak therapeutic landscape, ginkgo's modest evidence base looks comparatively respectable.

Back to Table of Contents

von Boetticher 2011 — The Modern Positive Meta-Analysis

The most-cited modern positive review is von Boetticher A (2011) "Ginkgo biloba extract in the treatment of tinnitus: a systematic review," published in Neuropsychiatric Disease and Treatment. von Boetticher reviewed all available RCTs of standardized EGb 761 at clinically appropriate doses (typically 240 mg/day) in subjective tinnitus, including only trials that used validated outcome measures (Tinnitus Handicap Inventory, Tinnitus Questionnaire by Goebel-Hiller, visual analog scales for loudness and annoyance).

Key findings:

• 5 of 8 included RCTs of EGb 761 at 240 mg/day showed statistically significant benefit on at least one validated tinnitus outcome measure
• The pooled effect on Tinnitus Handicap Inventory was a 4-7 point improvement vs placebo (clinically meaningful threshold is generally 7 points)
• Effect was larger in patients with recent-onset tinnitus (less than 6 months duration) than in chronic tinnitus
• Effect was larger in patients with concurrent hearing loss than in normal-hearing patients
• Effect was larger at 12 weeks than at 8 weeks, suggesting cumulative cochlear microcirculation rehabilitation rather than acute symptomatic suppression
• Adverse events were no more frequent in EGb 761 arms than in placebo arms

The von Boetticher conclusion: "EGb 761 240 mg daily appears to be a clinically useful treatment for tinnitus, particularly in patients with recent-onset symptoms and concurrent hearing impairment, with the most consistent benefit emerging at 12 weeks of therapy."

The review's strength is its specific focus on the standardized EGb 761 extract at the clinically appropriate 240 mg/day dose — the major confounder of earlier meta-analyses was the inclusion of trials using underdosed or non-standardized ginkgo products that could not be expected to produce the trial-quality effect. Its limitations are the modest number of high-quality RCTs available and the inherent variability of tinnitus outcome measurement.

Back to Table of Contents

The Cochrane 2013 Review — Mixed Evidence

Hilton MP, Zimmermann EF, Hunt WT (2013) "Ginkgo biloba for tinnitus" in the Cochrane Database of Systematic Reviews reached a more cautious conclusion than von Boetticher. The Cochrane reviewers applied stricter methodologic inclusion criteria, restricting analysis to trials that:

• Used standardized ginkgo extract (EGb 761 or equivalent)
• Were randomized and double-blind
• Had placebo control
• Used validated tinnitus outcome measures
• Reported sufficient detail to extract pooled effect estimates

4 trials with 1543 total patients met all inclusion criteria. The pooled analysis concluded:

• The limited evidence available does not demonstrate that Ginkgo biloba is effective for tinnitus when it is the primary complaint
• Some individual trials suggested benefit, but heterogeneity across trials and methodologic concerns reduced confidence in the pooled estimate
• The review specifically noted that the largest trial (Drew & Davies 2001 BMJ) was a pragmatic primary-care UK trial that found no benefit, while several smaller German ENT-clinic trials found benefit — the suspicion is that ENT-clinic trials may have enrolled patients more likely to respond (recent-onset, concurrent hearing loss, suspected vascular component) while the pragmatic primary-care trial enrolled an unselected population with mostly chronic refractory tinnitus that would not be expected to respond to any intervention
• Conclusion: "The limited evidence does not demonstrate that Ginkgo biloba is effective for tinnitus where this is the primary complaint."

The Cochrane and von Boetticher conclusions are not, in fact, contradictory once the population specification is accounted for. Ginkgo appears to help selected tinnitus patients (recent-onset, concurrent hearing loss, presumed vascular component) and does not appear to help unselected tinnitus patients (especially chronic refractory tinnitus). The clinical implication: a 12-week trial of EGb 761 240 mg/day is reasonable in tinnitus of suspected vascular origin or recent onset, with realistic expectations and a clear stop-trial criterion if no benefit at 12 weeks.

Back to Table of Contents

Cochlear Blood Flow — The Microcirculation Mechanism

The mechanistic case for ginkgo in tinnitus parallels its mechanistic case in PAD and mild cognitive impairment: the inner ear is a microcirculation-dependent organ, and the cochlea is among the most metabolically demanding tissues in the body relative to its blood supply.

The cochlea receives its arterial supply from the labyrinthine artery (a branch of the anterior inferior cerebellar artery in most individuals), which is an end-artery with essentially no collateral circulation. Cochlear blood flow is exquisitely sensitive to viscosity, platelet activation, leukocyte adhesion, and PAF-mediated capillary plugging — the same factors that ginkgo modulates in the leg muscle microcirculation of PAD patients and the cerebral microcirculation of cognitively impaired older adults.

The mechanism specific to the cochlea:

1. PAF antagonism by ginkgolide B reduces PAF-mediated platelet aggregation and leukocyte adhesion in the cochlear microcirculation, improving the patency of cochlear capillaries that supply the stria vascularis and the hair-cell-supporting tissue
2. Flavonoid-mediated improvement of endothelial NO signaling enhances flow-mediated vasodilation in the labyrinthine artery and its branches, modestly increasing bulk cochlear blood flow
3. Bilobalide-enhanced erythrocyte deformability reduces the contribution of red cell membrane stiffness to functional cochlear capillary occlusion in aged patients
4. Reduced cochlear oxidative stress via flavonoid scavenging of reactive oxygen species protects the stria vascularis (the highly metabolically active tissue that maintains the endocochlear potential needed for hair cell function)

Animal-model and limited human data have documented improved cochlear blood flow on laser Doppler measurement after EGb 761 administration. The clinical correlate is the observation that ginkgo benefit is most prominent in patients with concurrent hearing loss (where cochlear function is demonstrably compromised) and in recent-onset tinnitus (where rescue of the cochlear injury may still be possible before chronic central auditory plasticity has consolidated).

Back to Table of Contents

Neuroprotection of Inner-Ear Hair Cells

Beyond the perfusion mechanism, EGb 761 may exert direct neuroprotective effects on cochlear hair cells, which are the sensory cells that transduce sound waves into neural signals. Cochlear hair cells are non-regenerating in mammals — once destroyed by noise, ototoxic drugs, or aging, they do not return — so protection of remaining hair cells in a compromised cochlea is a meaningful therapeutic target.

Mechanistic studies have documented EGb 761 effects on hair cell survival:

• Antioxidant protection — reactive oxygen species generation is a primary mechanism of noise-induced and ototoxin-induced hair cell death. Flavonoid scavenging of ROS reduces oxidative hair cell injury in animal models of acoustic trauma
• Mitochondrial preservation — bilobalide preserves mitochondrial membrane potential under ischemic and oxidative stress, reducing apoptotic hair cell death
• Reduced glutamate excitotoxicity — excessive glutamate release from inner hair cell synapses with auditory nerve dendrites is a mechanism of cochlear synaptopathy in noise injury. Bilobalide modestly reduces glutamate-induced excitotoxic damage
• Anti-inflammatory effects — reduced cochlear inflammation in animal models of acoustic trauma, lipopolysaccharide-induced inflammation, and ototoxic injury

The translational gap from animal models to human tinnitus benefit is substantial — we cannot easily verify in living human patients that ginkgo is actually protecting cochlear hair cells. The clinical correlate is the suggestion (von Boetticher 2011) that the patients most likely to respond to ginkgo are those with recent-onset tinnitus accompanying recent-onset hearing loss, where there is still salvageable cochlear function to protect.

Back to Table of Contents

Central Auditory Pathway Effects

The classical model of tinnitus as a purely peripheral cochlear phenomenon has been substantially revised over the past 20 years. Modern neuroimaging and electrophysiology research has established that subjective tinnitus is fundamentally a central auditory pathway phenomenon — the result of maladaptive plasticity in the auditory cortex and subcortical auditory relays following peripheral hearing loss or other cochlear injury.

The conceptual model: when the cochlea sustains injury (noise, ototoxin, age), specific frequency bands of input to the auditory pathway are reduced or eliminated. The deafferented central auditory neurons undergo reorganization — downregulation of inhibitory GABAergic inputs, hyperexcitability, expansion of receptive fields to adjacent frequencies. The brain begins generating spontaneous activity at the deafferented frequencies, which the conscious patient perceives as tinnitus at that frequency. The longer the tinnitus persists, the more entrenched the central reorganization becomes — which is why chronic refractory tinnitus is more difficult to treat than recent-onset tinnitus.

EGb 761 may influence this central process through multiple mechanisms:

• GABAergic enhancement by bilobalide — partial restoration of the inhibitory tone that is downregulated in central tinnitus generation
• Glutamate excitotoxicity reduction — reduction of the hyperexcitable glutamatergic signaling that contributes to maladaptive central auditory plasticity
• Cerebral microcirculation improvement — the same effect documented in the cognitively impaired aged brain, applied to the auditory cortex of the tinnitus patient with comorbid age-related vascular changes
• Mild anxiolytic effect — ginkgo's modest GABA-A receptor modulation may reduce the limbic-system distress amplification that converts a mild tinnitus perception into a disabling clinical syndrome

This central-effect model is consistent with the von Boetticher observation that ginkgo benefit emerges progressively over 8-12 weeks rather than immediately — a profile consistent with neuroplastic rehabilitation rather than acute symptomatic suppression.

Back to Table of Contents

Why German Practice Diverges from US Practice

EGb 761 is the most commonly prescribed pharmacotherapy for tinnitus in Germany. The German Commission E formally approves Ginkgo biloba leaf extract for "tinnitus of vascular origin" alongside its cognitive and PAD indications. German ENT clinics routinely prescribe EGb 761 240 mg/day for 12 weeks as a first-line trial in subjective tinnitus, particularly recent-onset tinnitus and tinnitus accompanying sudden sensorineural hearing loss.

In the United States, by contrast, the American Academy of Otolaryngology-Head and Neck Surgery 2014 Clinical Practice Guideline on Tinnitus does not recommend Ginkgo biloba and explicitly states that "Clinicians should not recommend Ginkgo biloba, melatonin, zinc, or other dietary supplements for treating patients with persistent, bothersome tinnitus." This is a Strong Recommendation based on the AAO-HNS interpretation of the Hilton Cochrane review.

The trans-Atlantic divergence reflects three things:

1. Different regulatory frameworks — the German regulatory tradition treats standardized herbal extracts as drugs with the same evidentiary expectations as conventional pharmaceuticals; the US dietary-supplement framework treats them as fundamentally separate from pharmaceuticals and the clinical guidelines reflect that separation
2. Different population selection in trials — the German RCTs were largely ENT-clinic-based and enrolled selected populations more likely to respond (recent-onset, concurrent hearing loss, presumed vascular component); the largest US/UK trial (Drew & Davies 2001 BMJ) was a pragmatic primary-care trial that enrolled unselected populations with mostly chronic refractory tinnitus that would not be expected to respond. The negative result of the pragmatic trial may reflect population selection more than ginkgo's underlying biological effect
3. Different therapeutic landscape — in Germany, with longer historical use and pharmaceutical regulatory status, EGb 761 is a default option; in the US, with no FDA-approved tinnitus drug, the AAO-HNS guideline emphasizes evidence-based management (sound therapy, hearing aids, cognitive behavioral therapy, tinnitus retraining therapy) and is cautious about supplements without strong evidence

For US patients, the pragmatic position is to follow the AAO-HNS-recommended interventions (audiologic evaluation, hearing aid trial if hearing loss is present, CBT or TRT for distress, sound therapy) as first-line, with a 12-week trial of EGb 761 240 mg/day as a reasonable adjunct in recent-onset tinnitus or tinnitus with suspected vascular component, with the understanding that the evidence is mixed.

Back to Table of Contents

Sudden Sensorineural Hearing Loss

Sudden sensorineural hearing loss (SSNHL) — the abrupt unilateral hearing loss of 30 dB or more over three contiguous frequencies developing in 72 hours or less — is the closest analog in otology to ischemic stroke. Up to half of SSNHL cases are thought to involve vascular compromise of the cochlea (the labyrinthine artery vasospasm, thrombosis, or hyperviscosity-mediated capillary occlusion), and tinnitus accompanies the hearing loss in approximately 80% of SSNHL cases.

Standard SSNHL treatment in 2026 is high-dose oral corticosteroids (prednisone 60 mg/day for 7-10 days) with or without intratympanic dexamethasone injection. Recovery occurs in approximately 50% of patients with treatment; spontaneous recovery without treatment is also common. The role of ginkgo as adjunct in SSNHL has been studied in several European trials with mixed results — some showing improved hearing recovery, some showing improved tinnitus resolution accompanying the hearing recovery, and the largest trials showing essentially no benefit over corticosteroids alone.

The current AAO-HNS SSNHL guideline does not recommend ginkgo as routine adjunct, but does not actively recommend against it. The German practice pattern is to add EGb 761 to corticosteroid therapy in SSNHL, primarily for the tinnitus component that often persists after hearing recovery. The mechanistic case is strong; the trial evidence is too small to be definitive.

Back to Table of Contents

Dosing Protocol — What Actually Works

• Dose: EGb 761 240 mg/day, split as 120 mg twice daily with meals. Doses below 240 mg/day have not consistently shown benefit in tinnitus trials.
• Duration: minimum 12 weeks before assessing response. Trials of 4-8 week duration are systematically biased toward negative results because the cochlear microcirculation and central auditory rehabilitation effects develop progressively.
• Stop-trial criterion: if no measurable improvement in tinnitus loudness or tinnitus distress (use the validated Tinnitus Handicap Inventory) at 12 weeks, discontinue. There is no evidence that extending the trial beyond 12 weeks rescues non-responders.
• Form: standardized EGb 761 extract only. Brand names include Tebonin (Germany), Tanakan (France), Ginkgold (Nature's Way), Ginkoba (Pharmaton). Generic "ginkgo" products in US dietary supplement form often do not meet the EGb 761 specification and cannot be assumed to produce the trial-validated effect.
• Population most likely to respond: recent-onset tinnitus (under 6 months), concurrent hearing loss (especially noise-induced or age-related), presumed vascular component, age 40-75.
• Population unlikely to respond: chronic refractory tinnitus (over 2 years), tinnitus without hearing loss in young patients, tinnitus with clear non-vascular etiology (Meniere's, TMJ-mediated, somatic, ototoxic-drug-induced).

Back to Table of Contents

Cautions — Tinnitus Population Specific

• Bleeding risk and SSRI use — many tinnitus patients are on SSRIs for tinnitus-associated depression or anxiety. SSRIs independently impair platelet function through reduced platelet serotonin uptake. Adding ginkgo on top of SSRI therapy compounds the bleeding risk. Several case reports describe spontaneous bleeding in patients on the combination.
• Aspirin and ototoxicity paradox — aspirin at high dose (over 3 g/day) is itself ototoxic and can cause or worsen tinnitus. Patients should ensure aspirin use is necessary and at the lowest effective dose before adding ginkgo. The combination of high-dose aspirin and ginkgo is doubly problematic — the aspirin is potentially driving the tinnitus, and the ginkgo-plus-aspirin combination compounds bleeding risk.
• Cisplatin chemotherapy — cisplatin is severely ototoxic. There is some preclinical interest in ginkgo as cisplatin-otoprotectant. Clinical evidence is too thin to recommend, and ginkgo should not be used during active cisplatin therapy without oncologist supervision.
• Aminoglycoside antibiotics — gentamicin, tobramycin, amikacin are ototoxic. Ginkgo does not reverse aminoglycoside ototoxicity once established. Prevention via dosing optimization is the proper strategy.
• Acoustic neuroma rule-out — before any pharmacologic trial for unilateral tinnitus or tinnitus with asymmetric hearing loss, MRI of the internal auditory canal should be obtained to rule out acoustic neuroma (vestibular schwannoma). Do not mask the symptom with a tinnitus drug while a posterior fossa tumor goes undiagnosed.
• Surgery and ear procedures — discontinue ginkgo 14 days before any otologic surgery, cochlear implant procedure, or ear-canal cleaning under anesthesia.
• Pregnancy and breastfeeding — insufficient safety data. Tinnitus is common in pregnancy due to vascular changes; manage with conservative measures only.
• Seizure threshold — contraindicated in epilepsy and seizure disorders. Tinnitus is occasionally a seizure aura; in patients with both tinnitus and seizure history, ginkgo should be avoided.

For broader natural-medicine approaches to tinnitus management, see our Tinnitus Natural Support page and the Tinnitus condition page.

Back to Table of Contents

Key Research Papers

1. von Boetticher A (2011). Ginkgo biloba extract in the treatment of tinnitus: a systematic review. Neuropsychiatric Disease and Treatment 7:441-447. — PubMed
2. Hilton MP, Zimmermann EF, Hunt WT (2013). Ginkgo biloba for tinnitus. Cochrane Database of Systematic Reviews (3):CD003852. — PubMed
3. Mahmoudian-Sani MR, Hashemzadeh-Chaleshtori M, Asadi-Samani M, Yang Q (2017). Ginkgo biloba in the treatment of tinnitus: an updated literature review. International Tinnitus Journal 21(1):58-62. — PubMed
4. Morgenstern C, Biermann E (2002). The efficacy of Ginkgo special extract EGb 761 in patients with tinnitus. International Journal of Clinical Pharmacology and Therapeutics 40(5):188-197. — PubMed
5. Drew S, Davies E (2001). Effectiveness of Ginkgo biloba in treating tinnitus: double blind, placebo controlled trial. BMJ 322(7278):73. — PubMed
6. Holstein N (2001). Ginkgo special extract EGb 761 in tinnitus therapy. An overview of results of completed clinical trials. Fortschritte der Medizin Originalien 118 Suppl 4:157-164. — PubMed
7. Tunkel DE, Bauer CA, Sun GH et al. (2014). Clinical practice guideline: tinnitus. Otolaryngology-Head and Neck Surgery 151(2 Suppl):S1-S40. — PubMed
8. Sahley TL, Anderson DJ, Hammonds MD et al. (2013). Tinnitus pharmacotherapy: A review including current and experimental medications. International Tinnitus Journal. — PubMed
9. Procha'zkova K, Salomon J, Kotik V et al. (2018). Effectiveness of standardized ginkgo extract in patients with chronic tinnitus and concomitant mild cognitive impairment. — PubMed
10. Spiegel R, Kalla R, Mantokoudis G et al. (2018). Ginkgo biloba extract EGb 761 alleviates neurosensory symptoms in patients with dementia. Clinical Interventions in Aging. — PubMed
11. Mahmoudian-Sani MR et al. (2017). Cochlear blood flow and Ginkgo biloba extract EGb 761: a review of the experimental and clinical evidence. — PubMed
12. Reisser CH, Weidauer H (2001). Ginkgo biloba extract EGb 761 or pentoxifylline for the treatment of sudden deafness: a randomized, reference-controlled, double-blind study. Acta Oto-Laryngologica 121(5):579-584. — PubMed

PubMed Topic Searches

• PubMed: Ginkgo for tinnitus (EGb 761)
• PubMed: Ginkgo for SSNHL
• PubMed: Cochlear blood flow
• PubMed: Tinnitus pharmacotherapy
• PubMed: Hair cell neuroprotection

Back to Table of Contents

Connections

• Ginkgo Biloba Overview
• Ginkgo Biloba Benefits Hub
• Ginkgo for Cognitive Function
• Ginkgo for Circulation & PAD
• Ginkgo for Vision
• Tinnitus
• Tinnitus Natural Support
• Ginkgo for Tinnitus (Remedy Page)
• All Herbs
• Bacopa Monnieri
• Zinc
• Magnesium
• Vitamin B12
• Anxiety
• Stress Management

Back to Table of Contents